1 October 2020 - The US Food and Drug Administration has broadened its investigation of a serious illness in AstraZeneca's COVID-19 vaccine study and will look at data from earlier trials of similar vaccines developed by the same scientists, three sources familiar with the details told Reuters.

AstraZeneca's large, late-stage US trial has remained on hold since September 6, after a study participant in Britain fell ill with what was believed to be a rare spinal inflammatory disorder called transverse myelitis.

Australian regulators will be watching the progress of AstraZeneca's vaccine development closely given the government has brokered a deal for biotechnology giant CSL to make 30 million doses of the product in Melbourne if it works.

Read Sydney Morning Herald article